Indian Journal of Nuclear Medicine

: 2020  |  Volume : 35  |  Issue : 3  |  Page : 238--240

Idiopathic hepatic and splenic uptake of 99mTc-methylene diphosphonate

Lokeshwaran Madurai Kalimuthu, Aftab Hasan Nazar, Prasanta Kumar Pradhan 
 Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Correspondence Address:
Prof. Prasanta Kumar Pradhan
Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh


Tc-99m-methylene diphosphonate (MDP) bone scintigraphy is mainly directed toward identifying sites of altered skeletal metabolism and abnormal foci of calcium phosphate deposition due to various etiologies. One of the requirements of an ideal bone scintigraphy is little or no extraosseous uptake. Nonosseous uptake of MDP in the bone scintigraphy is an unusual finding. We report a case of carcinoma prostate referred for bone scan, where diffuse hepatic and splenic uptake has been seen on the bone scan. However, on a further repeat bone scan, there was no nonosseous uptake.

How to cite this article:
Kalimuthu LM, Nazar AH, Pradhan PK. Idiopathic hepatic and splenic uptake of 99mTc-methylene diphosphonate.Indian J Nucl Med 2020;35:238-240

How to cite this URL:
Kalimuthu LM, Nazar AH, Pradhan PK. Idiopathic hepatic and splenic uptake of 99mTc-methylene diphosphonate. Indian J Nucl Med [serial online] 2020 [cited 2021 Apr 15 ];35:238-240
Available from:

Full Text

A 67-year-old man, with type II diabetes mellitus for 25 years and hypertension for 15 years (on regular medication), biopsy-proven case of carcinoma prostate, was referred for bone scintigraphy to rule out the possibility of bone metastasis. He presented with complaints of low backache and swelling associated with pain in the left ankle for 2 months. The previous bone scintigraphy revealed increased osteoblastic activity at bilateral acetabulum and left ischium – metastatic. Ultrasonography of the abdomen and pelvis revealed Grade II prostatomegaly. Magnetic resonance imaging pelvis revealed features suggestive of carcinoma prostate with bony metastasis. The patient is on hormonal therapy for the past 1 year with no history of chemotherapy or radiotherapy. Biochemical investigations such as serum electrolyte, calcium, phosphate, creatinine, lactate dehydrogenase, and alkaline phosphate levels were in the normal limit during both the initial and repeat bone scans. The bone scan revealed diffuse and intense tracer uptake in the liver and, to a lesser degree, in the spleen. Relatively decreased skeletal uptake on the bone scan was also observed with foci of increased radiopharmaceutical uptake in the left pubic bone and the left side of the mandible [Figure 1].{Figure 1}

Single-photon emission computerized tomography/computed tomography ( SPECT/CT) of the pelvic region revealed increased radiopharmaceutical uptake in the superior rami of the left pubic bone with subtle sclerotic changes on low-dose CT. The bone scan of other patients done on the same day did not reveal such abnormal nonosseous tracer uptake.

A repeat bone scintigraphy with SPECT/CT of the pelvic region was performed 1 month later. There was considerably more skeletal uptake, and hepatic and splenic radiopharmaceutical localization was absent. Tc-99m-methylene diphosphonate (MDP) bone scintigraphy is routinely performed nuclear medicine procedure in the workup of a patient with carcinoma.[1] Increased radiopharmaceutical uptake is seen in lesions having increased osteoblastic activity. Due to urinary excretion of Tc-99m-MDP radiopharmaceutical, kidneys and urinary bladder are generally visualized [Figure 2].{Figure 2}

Hepatic and splenic uptake of 99m Tc-MDP is an unusual finding in nuclear medicine practice, occurring less frequently than focal hepatic abnormalities. [Table 1] lists several reported causes of diffuse hepatic uptake.[2]{Table 1}

The most common reason in the current clinical scenario is scintigraphic studies involving the use of Tc-99m-tagged colloid radiopharmaceuticals on the previous day to the bone scintigraphic study or misadministration of the radiopharmaceutical like 67 Ga-citrate or 111 In-labeled white blood cells. However, the patient did not have any scintigraphic study with radiocolloid on the previous day, and also, misadministration/delayed administration was also excluded. Metastatic calcification in soft tissue is mainly due to hypercalcemia. This can be due to increased secretion of parathormone, Vitamin D-related disorders, renal failure, and/or aluminum toxicity. These causes are ruled out due to normal biochemical profile. Faulty radiopharmaceutical preparations such as the formation of a Tc-99m colloid complex may be the cause of reticuloendothelial tissue uptake.[3]99m Tc colloid may be formed in the presence of excessive aluminum ion or when excessive hydrolyzed-reduced 99m Tc colloid from any cause is present. This radiochemical contaminant will localize in the extraosseous sites such as liver, spleen, or bone marrow if it is present in sufficient quantity in the 99m Tc-MDP. Other causes could be iron overload,[4] iodinated-based or gadolinium contrast study just before bone scintigraphy,[5] and severe hepatic necrosis.[6],[7]

Pathologic changes occur due to change in the normal physiological event. Extraosseous localization of the bone-seeking radiopharmaceuticals in tissues other than kidney and urinary bladder should raise a suspicion of the underlying cause, and pathophysiological basis of pathology should always be kept in mind while interpreting the scan as it may have a tremendous impact on the further management and follow-up of the patient. Recognition of specific mechanisms and appearance of soft-tissue abnormalities on skeletal scintigraphy reduces the possibility of confusion and enhances the diagnostic value of the study.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial Support and Sponsorship


Conflicts of interest

There are no conflicts of interest.


1Francis MD, Graham R, Russell G, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969;165:1264-6.
2Verma S, Kumar N, Kheruka SC, Gambhir S. Extraosseous 99mTc-methylene diphosphonate uptake on bone scan: Unusual scenario. Indian J Nucl Med 2016;31:280-2.
3MacDonald J. Idiopathic hepatic uptake of 99mTc methylene diphosphonate: A case report. J Nucl Med Technol 2001;29:6.
4Hung JC, Ponto JA, Hammes RJ. Radiopharmaceutical-related pitfalls and artifacts. Semin Nucl Med 1996;26:208-55.
5Pérez-Lago del MS, De Vírgala MC, Siurana R, Ferrando MJ, Danús M, Izquierdo V, et al. Altered biodistribution of bone seeking agents in the presence of iron-overload. Clin Nucl Med 2004;29:214.
6Zhang W, Chen B, Deng H, Yang T, Ou X. Hepatic and splenic uptake on bone scintigraphy in patients with intravenous administration of 99mTc methylene diphosphonate prior to gadolinium-containing contrast. Clin Nucl Med 2013;38:219-20.
7Shih WJ, Coupal J. Diffuse and intense Tc-99m HMDP localization in the liver due to hypoxia secondary to respiratory failure. Clin Nucl Med 1994;19:116-20.